Fast Track designations were granted by the FDA for the oral and intravenous formulations of Amplyx Pharmaceuticals' fosmanogepix, or APX001. The antifungal can be used as a treatment for seven indications, which include coccidioidomycosis, cryptococcosis, fusariosis, invasive aspergillosis, invasive candidiasis, mucormycosis, and scedosporiosis.
FDA grants Fast Track status to fosmanogepix's oral, IV formulations
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.